Another patient has suffered from a number of saxagliptin side effects, including heart failure from Onglyza, which has led to a new lawsuit.

The plaintiff, Donielle C., began taking Onglyza at the direction of her doctor in 2015. Donielle was prescribed Onglyza (saxagliptin) in order to treat type-2 diabetes, helping to lower her blood sugar levels.

Unfortunately, sometime after Donielle began taking Onglyza, she suffered “significant bodily and mental injuries,” the lawsuit claims. Indeed, according to the lawsuit, Donielle experienced heart failure from Onglyza, as well as other injuries.

These injuries have had a substantial effect: pain and suffering, mental anguish, disfigurement, inconvenience, lost wages and medical expenses, as well as others.

In her lawsuit, Donielle claims that Bristol-Myers Squibb, Onglyza’s manufacturer, was aware that its drug was linked to heart failure and other serious injuries, yet continued to market the drug as safe and effective.

According to the lawsuit, Bristo-Myers Squibb “knowingly, purposely, and deliberately failed to adequately warn [Donielle], patients, consumers, medical providers, and the public of the increased risk of serious injury associated with using saxagliptin, including, but not limited to” heart failure from Onglyza.

Onglyza Side Effects

A growing number of type-2 diabetes patients like Donielle and even their family members are reporting Onglyza complications linked with the popular diabetes medication. Some have begun filing lawsuits against the drug manufacturer over heart failure from Onglyza and other complications, alleging that they were not adequately warned of the risks.

Background of Onglyza

Onglyza (also known as saxagliptin, its generic name) is a popular type-2 diabetes treatment, and is manufactured by Bristol-Myers Squibb.

Onglyza is a relatively new drug, and was first approved by the U.S. Food and Drug Administration (FDA) just in 2009. Since its release onto the market, the popularity of Onglyza has steadily increased.

Sales of this diabetes drug are projected to reach $2 billion annually in the near future, despite being available for under a decade. Incretin mimetics like Onglyza are used to mimic the body’s natural incretin hormones, which stimulates insulin releasing after a meal, helping to control the blood sugar level of a diabetes patient.

Despite the popularity of incretin mimetics, these drugs have been linked with serious complications, including heart failure from Onglyza. Indeed, a recent study shows a link between these diabetes drugs and an increased risk of heart failure and hospitalization.

Even a study funded by the manufacturers of the drug found that patients who used saxagliptin faced a higher rate of heart failure-related hospitalizations.

The study was published in the New England Journal of Medicine in 2013, and found that patients who took Onglyza were more likely to be hospitalized due to heart failure than those who took other medications.

Filing a Lawsuit Over Heart Failure from Onglyza

If you or someone you love has suffered or died from heart failure from Onglyza or other serious side effects, you may be able to take legal action.

Filing an Onglyza lawsuit cannot take away the pain and suffering caused by heart failure from Onglyza, but it can help to alleviate financial costs from medical expenses and lost wages.

The Heart Failure from Onglyza Lawsuit is Case No. 3:17-cv-03180-JCS, in the U.S. District Court for the Northern District of California.